IL17A and COVID-19: Recently, studies have appeared in the literature on the cytokine profile in COVID-19 patients treated with MSCs, showing significantly reduced levels of proinflammatory cytokines (e.g., IL-6, IFN-γ, TNF-α, and IL-17A) and increased plasma anti-inflammatory cytokines levels (including IL-10 and TGF-β) observed after infusion of those stem cells.